Shares of the global healthcare company, Novartis , are down after it saw its profits fall in the second quarter. The pharmaceuticals company saw earnings of $1.23 a share, which was four cents better than forecasts. The company is dealing with falling sales of its cancer drug, while its new heart drug has had a disappointing start in the U.S. Novartis also said its sales in 2016 will be “broadly in line” with last year’s while core operating profit is expected to either be flat or decline.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
